Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

BACKGROUND: Lapatinib is a dual inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER-2) tyrosine kinases. This study investigated the pharmacodynamic and clinical effects of lapatinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: del Campo, J M, Hitt, R, Sebastian, P, Carracedo, C, Lokanatha, D, Bourhis, J, Temam, S, Cupissol, D, De Raucourt, D, Maroudias, N, Nutting, C M, Compton, N, Midwinter, D, Downie, L, Biswas-Baldwin, N, El-Hariry, I, Harrington, K J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188940/
https://www.ncbi.nlm.nih.gov/pubmed/21829197
http://dx.doi.org/10.1038/bjc.2011.237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3188940/
https://www.ncbi.nlm.nih.gov/pubmed/21829197
http://dx.doi.org/10.1038/bjc.2011.237

Ejemplares similares